🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the fight against superbug strains of the bacteria, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are on the rise around the world, with estimates suggesting more than 82 million infections per year. Notably increased rates are observed in Africa and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an important and timely advancement in the reality of rising global incidence, increasing antimicrobial resistance and the very limited treatment choices presently on offer.”

Public health authorities are particularly alarmed about the surge in drug-resistant strains. The global health body has classified it as a "critical concern". Recent surveillance found that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Receive Authorization

Zoliflodacin, also known as a brand name, was cleared by the US FDA in December for use against gonorrhoea. This disease can lead to significant complications, including infertility. Researchers hope that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, gained clearance in concurrent days. This medication, which is employed against urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This approval marks a huge turning point in the management of highly resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Testing Outcomes and Global Access

As per results released by a major medical journal, the new drug successfully treated the vast majority of uncomplicated infections. This places it at an comparable level with the existing first-line therapy, which uses an injection and a pill. The trial enrolled hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the authority to license and sell the drug in a wide range of regions with limited resources.

Medical professionals directly involved have expressed positive views. Access to a single-dose, oral treatment such as this is hailed as a "game-changer" for public health efforts. This is considered essential to lessen the impact of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea worldwide.